PD-L1 Biomarkers
News and reporting on PD-L1 biomarkers.
Oncologists Bemoan 'Lousy' PD-L1 Biomarker in Light of New Adjuvant Tecentriq NSCLC Study Data
Premium
Updated results from IMpower010 showed NSCLC patients with PD-L1 expression in 1 to 49 percent of tumor cells derived less benefit from adjuvant Tecentriq than those with higher expression.
CHMP Recommends BMS' Opdivo Plus Chemo for First-Line PD-L1-Positive Gastric Cancers
The recommendation is for a narrower indication than is allowed in the US, where the FDA approved the regimen for patients regardless of PD-L1 status.
Hutchmed, BeiGene Launch US-Based Study of Fruquintinib, Tislelizumab in TNBC, Endometrial Cancer
The firms will evaluate the combination's safety and preliminary efficacy and perform a retrospective biomarker analysis on patients' tumor samples.
Merck Nets Two Keytruda Approvals in Japan for TNBC, Colon Cancer
Japanese regulators approved pembrolizumab for PD-L1-positive triple-negative breast cancer and microsatellite instability-high colorectal cancer patients.Â
Nouscom Begins Phase Ib Trial of Personalized Vaccine, Keytruda Combo in Melanoma, Lung Cancer
Researchers will assess the safety, anti-tumor activity, and immunogenicity of the combination in advanced melanoma and PD-L1-positive NSCLC patients.